Your browser doesn't support javascript.
loading
Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data.
Pulley, Jill M; Rhoads, Jillian P; Jerome, Rebecca N; Challa, Anup P; Erreger, Kevin B; Joly, Meghan M; Lavieri, Robert R; Perry, Kelly E; Zaleski, Nicole M; Shirey-Rice, Jana K; Aronoff, David M.
Affiliation
  • Pulley JM; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.
  • Rhoads JP; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.
  • Jerome RN; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.
  • Challa AP; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.
  • Erreger KB; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.
  • Joly MM; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.
  • Lavieri RR; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.
  • Perry KE; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.
  • Zaleski NM; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.
  • Shirey-Rice JK; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.
  • Aronoff DM; Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
Annu Rev Pharmacol Toxicol ; 60: 333-352, 2020 01 06.
Article in En | MEDLINE | ID: mdl-31337270
ABSTRACT
The promise of drug repurposing is to accelerate the translation of knowledge to treatment of human disease, bypassing common challenges associated with drug development to be more time- and cost-efficient. Repurposing has an increased chance of success due to the previous validation of drug safety and allows for the incorporation of omics. Hypothesis-generating omics processes inform drug repurposing decision-making methods on drug efficacy and toxicity. This review summarizes drug repurposing strategies and methodologies in the context of the following omics fields genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, phenomics, pregomics, and personomics. While each omics field has specific strengths and limitations, incorporating omics into the drug repurposing landscape is integral to its success.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pharmaceutical Preparations / Drug Repositioning Limits: Animals / Humans Language: En Journal: Annu Rev Pharmacol Toxicol Year: 2020 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pharmaceutical Preparations / Drug Repositioning Limits: Animals / Humans Language: En Journal: Annu Rev Pharmacol Toxicol Year: 2020 Type: Article Affiliation country: United States